Showing 8691-8700 of 10165 results for "".
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- Topix Pharmaceuticals Partners with New Mountain Capitalhttps://practicaldermatology.com/news/new-mountain-capital-partners-with-topix-pharmaceuticals/2458505/Topix Pharmaceuticals, Inc. has partnered with New Mountain Capital, LLC, a growth-oriented investment firm that currently manages over $15 billion in assets. New Mountain, a New York-based private equity firm, identified Topix through a proactive focus in the life sciences and aestheti
- It's Official: Botox Makes Us Feel Better About Ourselveshttps://practicaldermatology.com/news/its-official-botox-makes-us-feel-better-about-ourselves/2458516/Patient satisfaction with overall facial appearance increases by 28 percent with botulinum toxin type A injections to the glabellar rhytids, according to new research in the Aesthetic Surgery Journal. In the study, sati
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cite
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- Robert Grant No Longer CEO of Alphaeonhttps://practicaldermatology.com/news/robert-grant-no-longer-ceo-of-alphaeon/2458550/Robert Grant is no longer CEO of Alphaeon, our sister site, Eyewiretoday.com has learned. After 3 years at
- GlobalMed Technologies Acquires Omnilux Medicalhttps://practicaldermatology.com/news/globalmed-technologies-acquires-omnilux-medical/2458551/GlobalMed Technologies (GMT) has acquired Omnilux Medical, the gold standard for medical and aesthetic Light Emitting Diode (LED) skincare. The asset acquisition includes three Omnilux Medical Systems, the Omnilux Revive2™, Omnilux Blue™ and Omnilux Plus™,